News from our newspaper (Shenyang Daily, Shenyang Net reporter Fu Songyan) Nowadays, vaccine safety has become the focus of attention of Chinese people, and people are paying more and more attention to trustworthy vaccine products. The reassuring management process is the advantage of Liaoning Chengda Biological Co., Ltd. (referred to as Chengda Biological). With the management process of "ensuring that each vaccine is safe and reliable" and the technical level of "international level and domestic leading", Chengda biological has not only won the favor of Chinese people, but also has a very eye-catching performance in the world market and the "new third board" capital market.

Chengda Bio is currently the world's largest human rabies vaccine manufacturer, located in Shenyang Hunnan National High-tech Park. The company's annual production capacity of rabies vaccine for human use is 10 million and that of Japanese encephalitis vaccine is 10 million. All workshops have passed the national new version of GMP certification.

Since 2007, the company's products have maintained the first market share among similar products in China, and the market share reached more than 60% in 2011. The products have been exported to more than 20 countries and regions such as India, Pakistan, Thailand and the Philippines. The company's Japanese encephalitis vaccine ranks first in the domestic market share of Class II Japanese encephalitis vaccine. It has been registered in Thailand and Cambodia, and the registration in India is being processed.

In 2002, Chengda Bio introduced "Bioreactor Large-scale Cell Culture Vaccine Production Technology" from abroad. On the basis of digestion and absorption, through independent innovation, it has formed a core technology with independent intellectual property rights-"Bioreactor Large-scale Vaccine Preparation Process Platform Technology" has overcome the technical problem of large-scale cell culture preparation of high-quality vaccines in my country for more than ten years, and filled the domestic gap in vaccine production technology, reaching the international advanced level, breaking the long-term monopoly of multinational companies in my country's high-end human rabies vaccine.

Based on the company's core technology platform, the bivalent hemorrhagic fever with renal syndrome vaccine (Vero cells) independently developed by Chengda Biology has completed its clinical work and is ready to apply to the state for production approval. It has started to build a hemorrhagic fever vaccine production workshop in Shenyang factory in 2015 and will go on sale after passing the national certification.

On the one hand, Chengda Bio will accelerate the expansion of its product line in the next few years and supplement conventional vaccine varieties from a high starting point. The company is developing influenza vaccine, chicken pox vaccine, hepatitis A vaccine, etc. are in an orderly progress. The company has invested 30 million yuan to build a bacterial vaccine research and development center in Yizhuang, Beijing. The research and development center was put into use in June 2014. The first vaccine product developed is meningococcal vaccine. After that, it will successively develop 23-valent pneumonia vaccine and other bacterial vaccines. At that time, the company will complete the construction of viral vaccine (VERO cells, diploid cells and chicken embryo cells) technology platform and bacterial vaccine technology platform, and become one of the most complete vaccine research and development and production enterprises in China.